Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and ...

GeoVax Labs (GOVX) announced its endorsement of President Donald J. Trump’s Stargate Initiative, “which aims to harness advanced technologies ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have been given an average rating of “Buy” by the seven analysts ...

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company specializing in developing vaccines with a current market capitalization of $19.78 million, announced today that its shareholders have approved ...

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s ...

The upcoming Phase 2 trial will evaluate the efficacy of Gedeptin in combination with ICIs in patients with first-recurrence head and neck cancer. Key endpoints will include pathologic response rates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Completion of Enrollment in Booster Vaccine Study for Healthy Adult Volunteers GeoVax has successfully completed enrollment in its Phase 2 clinical trial evaluating GEO-CM04S1 as a booster vaccine ...